Recent major advances in cardiovascular pharmacotherapy
| Autor: | James Milner, Julie Reis, Márcia de Borba Campos, Andreia Cunha, Carlota Gamboa-Cruz, Natália António |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
animal structures
Hypercholesterolemia Tetrazoles 030204 cardiovascular system & hematology Bioinformatics Approved drug Coronary artery disease Angiotensin Receptor Antagonists 03 medical and health sciences 0302 clinical medicine Pharmacotherapy medicine Humans Pharmacology (medical) 030212 general & internal medicine Pharmacology business.industry Aminobutyrates PCSK9 Biphenyl Compounds PCSK9 Inhibitors General Medicine medicine.disease Proprotein convertase Drug Combinations Valsartan Cardiovascular Diseases Heart failure Kexin Neprilysin business medicine.drug |
| Zdroj: | European Journal of Clinical Pharmacology. 74:853-862 |
| ISSN: | 1432-1041 0031-6970 |
| Popis: | The field of cardiovascular pharmacotherapy remains extremely active. The aim of this review is to summarize the recent major advances in cardiovascular pharmacotherapy, with a focus on (1) the new approved drug for treatment of heart failure with reduced ejection fraction-sacubitril/valsartan; (2) proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors; (3) the novel reversal agents for non-vitamin K oral anticoagulants (NOACs); and finally, (4) new evidence on pharmacological treatment of coronary artery disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink